triumph-1 retatrutide A summary slide of the data presented today by Dr. Ania Jastreboff at #ADA2026 🚨 TRIUMPH-1: Phase 3 Obesity Trial with Retatrutide 🚨 Retatrutide 💉, a once-weekly triple hormone receptor Triumph-1 Trial Results for Retatrutide

In human plasma GHK is present at about 200 micrograms/litre in men of age 20- 25 but declines to 80 micrograms/litre by age 60-80

The breadth of DSIPs biological activity spanning sleep regulation, stress modulation, pain processing, antioxidant defence, and neuroprotection has led some researchers to characterise it as an adaptogenic peptide: one that supports homeostatic balance across multiple physiological systems rather than acting on a single discrete target

Platlet rich plasma (PRP) improves fat grafting outcomes

All peptide use is screened, prescribed, and monitored by a medical provider

A pilot study and case reports on endometrial microbiota and pregnancy outcome: An analysis using 16S rRNA gene sequencing among IVF patients, and trial therapeutic intervention for dysbiotic endometrium